02162.HKEarnings•prnewswire•August 27, 2025 at 06:02 AM

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Sentiment:Positive (80)

Summary

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 27, 2025 by prnewswire